A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Kidney Cancer; Renal Cell Carcinoma

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03663946

CA209-8MK

Details and patient eligibility

About

Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world

Enrollment: 81 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with unresectable or metastatic renal cell carcinoma who are initiating treatment for the first time with Yervoy and Opdivo in accordance with the Japanese package insert will be included in this PMS

Exclusion criteria

• Patients receiving combination therapy with Yervoy and Opdivo for non RCC indication will be excluded from this PMS

Other protocol defined inclusion/exclusion criteria could apply

Trial design

81 participants in 1 patient group

Patients taking combination therapy with Yervoy and Opdivo

Description:

Medical records will be reviewed for safety and treatments for specific ADR

Treatment:

Other: Non-Interventional